ARK Investment Management LLC raised its holdings in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 363.5% in the fourth quarter, Holdings Channel reports. The institutional investor owned 290,922 shares of the biotechnology company’s stock after acquiring an additional 228,149 shares during the quarter. ARK Investment Management LLC’s holdings in Pluristem Therapeutics were worth $401,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the business. Jane Street Group LLC raised its stake in Pluristem Therapeutics by 15.0% in the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock valued at $402,000 after buying an additional 34,742 shares during the last quarter. Heritage Investors Management Corp purchased a new stake in Pluristem Therapeutics in the third quarter valued at about $113,000. Finally, Psagot Investment House Ltd. raised its stake in Pluristem Therapeutics by 1,705.2% in the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 122,347 shares during the last quarter. Institutional investors own 4.53% of the company’s stock.
A number of equities research analysts have commented on the company. Maxim Group set a $3.00 price target on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 21st. Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. ValuEngine cut Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 20th. Finally, HC Wainwright set a $4.00 price target on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $4.00.
COPYRIGHT VIOLATION WARNING: “Pluristem Therapeutics Inc. (PSTI) Shares Bought by ARK Investment Management LLC” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3227209/pluristem-therapeutics-inc-psti-shares-bought-by-ark-investment-management-llc.html.
Pluristem Therapeutics Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Want to see what other hedge funds are holding PSTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pluristem Therapeutics Inc. (NASDAQ:PSTI).
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.